News By Tag
News By Place
NAPSR news: AstraZeneca teams up with Advaxis for immuno-oncology combination clinical trial
AstraZeneca is global pioneer in the biopharmaceutical industry specializing in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.
The clinical trial (The Phase I/II immunotherapy study) will gauge the safety and efficacy of Medimmune’s investigational immunocancer therapy MEDI4736 and Advaxis’ cancer innmuotherapy vaccine, ADXS-HPV, a treatment for patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. According to a news release issued by AstraZeneca, “preclinical evidence suggests that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, can enhance overall anti-tumour response.”
“Our collaboration with Advaxis is further evidence of MedImmune’s commitment to explore novel combination approaches as we progress our immuno-oncology portfolio,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “We believe there could be an important clinical benefit from the combination of MEDI4736 with Advaxis’s antigen-specific cancer vaccine.”
The combination treatment will serve as an investigational therapy for the treatment of HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. In accordance with the terms and agreement, Phase I study of the trial will explore the dosage regimen of MEDI4736 with ADXS-HPV. The Phase 2 trial will assess safety and efficacy of combining both therapies.
“We are excited to be partnering with MedImmune and evaluating MEDI4736 in combination with our immunotherapy,”
With the evolution of technology it has been increasingly rampant throughout the industry for big pharma companies to join forces with biotech firms in order to discover and develop novel therapies and vaccines to combat life threating diseases and further expand their product pipeline.
The continuous research and development of this therapeutic breakthrough will certainly be life-changing for patients affected. If successful, pending regulatory approval, this combination treatment will join other effective therapies currently on the market. This will without a doubt bolster the need for both certified and qualified individuals to promote the company’s diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(